Zai Lab Ltd
Zai Lab Ltd (ticker: ZLAB) is a clinical-stage biopharmaceutical company focused on developing and commercialising therapies in oncology, autoimmune and infectious diseases. Listed under ticker ZLAB with a market capitalisation of about $3.28 billion, Zai Lab combines an in-house pipeline with partnered programmes to advance potential treatments through clinical trials. For investors, the key attractions are pipeline progress, potential regulatory approvals and partnerships that can de‑risk development cost and extend commercial reach. Equally important are the characteristic risks of the sector: clinical outcomes can be binary, regulatory hurdles are significant, and R&D spending can lead to variable near-term profitability. The company's performance is sensitive to trial readouts, pricing and reimbursement environments, and broader market sentiment toward biotechnology stocks. This summary is educational and not individual financial advice — suitability depends on your personal circumstances and risk tolerance, and investors should do further research and consider professional advice.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Zai Lab's stock, expecting it to rise significantly in value.
Financial Health
Zai Lab is performing well, showing strong revenue and cash flow, with a solid profit margin.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring ZLAB
China's Biopharma Innovators: The Next Global Partnership Wave
Following GSK's major licensing deal with China's Jiangsu Hengrui, a new investment theme is emerging around Chinese pharmaceutical innovators. This theme focuses on other Chinese biopharma companies that are likely to attract similar global partnerships, driving value through their advanced drug development pipelines.
Published: July 28, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Pipeline Catalysts
Clinical trial readouts and regulatory filings can drive material share-price moves, though outcomes can be binary and unpredictable.
Global Partnerships
Collaborations with larger pharma can broaden commercial reach and provide non‑dilutive funding, but depend on successful development and market access.
R&D Intensity
Heavy reinvestment into research is needed to advance candidates, offering upside if trials succeed and creating cash-burn risk if they do not.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
AbbVie Inc.
Abbvie is a research-based biopharmaceutical company that develops and markets advanced therapies to address complex medical conditions.
Amgen Inc.
Amgen is a global biotechnology company that focuses on discovering, developing and commercializing treatments for unmet medical needs.
ADMA BIOLOGICS INC
Develops products to treat immune deficiencies and chronic diseases.
